Ticker >

Themis Medicare share price

Themis Medicare Ltd.

NSE: THEMISMED BSE: 530199 SECTOR: Pharmaceuticals & Drugs  24k   58   5

212.85
+5.50 (2.65%)
NSE: 23 Apr 04:02 PM

Price Summary

Today's High

₹ 214.45

Today's Low

₹ 209

52 Week High

₹ 263.85

52 Week Low

₹ 132.61

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1959.07 Cr.

Enterprise Value

2032.18 Cr.

No. of Shares

9.2 Cr.

P/E

70.74

P/B

6.56

Face Value

₹ 1

Div. Yield

0.23 %

Book Value (TTM)

₹  32.45

CASH

18.85 Cr.

DEBT

91.96 Cr.

Promoter Holding

67.15 %

EPS (TTM)

₹  3.01

Sales Growth

-10.21%

ROE

16.49 %

ROCE

19.68%

Profit Growth

-29.67 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-10.21%
3 Year20.68%
5 Year11.08%

Profit Growth

1 Year-29.67%
3 Year39.61%
5 Year36.03%

ROE%

1 Year16.49%
3 Year20.23%
5 Year12.54%

ROCE %

1 Year19.68%
3 Year22.64%
5 Year15.9%

Debt/Equity

0.3264

Price to Cash Flow

121.88

Interest Cover Ratio

7.15960350073716

CFO/PAT (5 Yr. Avg.)

0.881630752988187

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 67.15 2.43
Dec 2023 67.16 2.43
Sep 2023 67.16 23.51
Jun 2023 67.16 23.51
Mar 2023 67.16 23.51
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 39.6055399769275% for the Past 3 years.
  • The company has shown a good revenue growth of 20.6824115989462% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.2259199443091% over the past 3 years.
  • Company has been maintaining healthy ROCE of 22.6428665273319% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of 63.1120928614743 days.
  • The company has a high promoter holding of 67.15%.

 Limitations

  • The company is trading at a high EV/EBITDA of 34.4293.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 88.78 80.11 96.65 104.78 82.51
Total Expenditure 73.51 69.62 74.9 92.38 74.45
Operating Profit 15.27 10.49 21.74 12.41 8.07
Other Income 5.9 2.95 0.65 2.44 0.57
Interest 2.23 2.71 2.49 2.04 2.69
Depreciation 2.67 2.8 3.03 3.07 3.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 16.27 7.93 16.88 9.74 2.85
Tax 4.19 1.89 4.32 2.64 0.85
Profit After Tax 12.09 6.04 12.56 7.1 2
Adjusted EPS (Rs) 1.31 0.66 1.36 0.77 0.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 184.11 201.59 230.67 394.61 354.32
Total Expenditure 181.54 165.91 180.79 298.96 286.86
Operating Profit 2.57 35.68 49.88 95.65 67.46
Other Income 2.69 3.47 3.62 6.54 11.5
Interest 11.82 12.88 12.71 8.77 9.56
Depreciation 7.98 8.27 8.55 9.48 10.49
Exceptional Items 0 0 0 0 0
Profit Before Tax -14.53 18.01 32.25 83.94 58.91
Tax -1.84 2.09 5.63 22.38 15.61
Net Profit -12.7 15.91 26.62 61.56 43.29
Adjusted EPS (Rs.) -1.38 1.73 2.9 6.69 4.7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 9.18 9.19 9.19 9.2 9.2
Total Reserves 134.16 150.13 176.61 234.28 272.62
Borrowings 9.35 11.85 22.2 23.88 28.45
Other N/C liabilities -6.64 -4.35 2.13 6.89 6.94
Current liabilities 146.65 154.79 128.27 123.48 149.32
Total Liabilities 292.7 321.61 338.4 397.74 466.54
Assets
Net Block 123.4 116.31 133.1 144 162.2
Capital WIP 2.45 7.54 2.47 2.56 2.6
Intangible WIP 0 0 0 0 0
Investments 11.02 10.96 10.98 11.01 11.07
Loans & Advances 2.67 2.91 2.83 6.9 12.81
Other N/C Assets 2.45 2.62 2.31 3.84 1.82
Current Assets 150.7 181.28 186.72 229.42 276.05
Total Assets 292.7 321.61 338.4 397.74 466.54
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -14.53 18.01 32.25 83.94 58.91
Adjustment 19.03 18.22 17.13 11.1 13.66
Changes in Assets & Liabilities 6.77 -35.65 7.52 -42.57 -40.34
Tax Paid -0.3 -0.24 0.08 -18.07 -16.15
Operating Cash Flow 10.97 0.33 56.98 34.39 16.07
Investing Cash Flow -3.79 -5.46 -15.65 -15.58 -23.96
Financing Cash Flow -9.94 6.72 -25.65 -17.55 0.14
Net Cash Flow -2.75 1.6 15.68 1.26 -7.75

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 67.16 67.16 67.16 67.16 67.15
anay rupen choksi 1.28 1.28 1.28 1.28 1.28
dinesh s patel huf 1.07 1.07 1.07 1.07 1.07
dinesh shantilal patel 9.48 9.48 9.48 9.48 9.47
gedeon richter investment... 9.61 9.61 9.61 9.61 9.61
jayshree d patel 7.26 7.26 7.26 7.26 7.25
nysha rupen choksi 1.28 1.28 1.28 1.28 1.28
reena s patel 4.04 4.04 4.04 4.04 4.04
sachin dinesh patel 5.99 5.99 5.99 5.99 5.99
shantilal dahyabhai patel... 0.61 0.61 0.61 0.61 0.61
themis distributors priva... 2.98 2.98 2.98 2.98 2.98
vividh distributors priva... 7.78 7.78 7.78 7.78 7.78
vividhmargi investments p... 15.79 15.79 15.79 15.79 15.78
gedeon richter investment... 9.61 9.61 9.61 9.61 9.61
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 32.84 32.84 32.84 32.84 32.85
anuj anantrai sheth 4.89 4.89 4.89 4.89 4.89
investor education and pr... - - 0.34 - 0.34
jagat navratna lodha - - - - 1.32
llp 0.43 - 0.66 0.40 0.40
za capital services india... 1.61 1.61 1.61 1.61 1.59
zafar ahmadullah - - - 2.34 2.34
investor education and pr... 0.34 0.34 - 0.34 -
jagat lodha 1.05 1.04 1.30 1.30 -
jewels advisory services ... - 1.09 1.35 1.23 -
zafar ahmadullah 2.34 2.34 2.34 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Themis Medicare informs about compliance certificate16 Apr 2024, 10:56AM Themis Medicare informs about certificate8 Apr 2024, 11:48AM Themis Medicare informs about newspaper publication 12 Mar 2024, 11:03AM Themis Medicare - Quaterly Results10 Feb 2024, 2:47PM Themis Medicare - Quaterly Results10 Feb 2024, 2:47PM Themis Medicare - Quaterly Results10 Feb 2024, 2:47PM Themis Medicare launches novel Opioid Injectable Analgesic ‘Remifentanil’10 Nov 2023, 3:42PM Themis Medicare informs about newspaper publication6 Nov 2023, 4:10PM Themis Medicare - Quaterly Results4 Nov 2023, 2:36PM Themis Medicare - Quaterly Results4 Nov 2023, 2:36PM Themis Medicare - Quaterly Results4 Nov 2023, 2:36PM Themis Medicare informs about newspaper publication17 Oct 2023, 12:20PM Themis Medicare informs about certificate 9 Oct 2023, 11:17AM Themis Medicare informs about closure of trading window28 Sep 2023, 12:51PM Themis Medicare incorporates wholly owned subsidiary20 Sep 2023, 2:22PM Themis Medicare - Quaterly Results10 Aug 2023, 3:18PM Themis Medicare - Quaterly Results10 Aug 2023, 3:18PM Themis Medicare - Quaterly Results10 Aug 2023, 3:18PM Themis Medicare informs about loss of share certificate26 Jun 2023, 11:59AM Themis Medicare informs about investors’ presentation15 May 2023, 10:51AM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare informs about compliance certificate17 Apr 2023, 4:03PM Themis Medicare informs about press release 17 Feb 2023, 3:31PM Themis Medicare gets DCGI’s nod to import, market Remifentanil 1mg/2mg Powder for Injection17 Feb 2023, 2:58PM Themis Medicare informs about analyst meet 17 Feb 2023, 10:33AM Themis Medicare informs about loss of share certificate9 Feb 2023, 5:14PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare informs about loss of share certificate2 Feb 2023, 2:52PM Themis Medicare informs about certificate11 Jan 2023, 3:11PM Themis Medicare launches novel transdermal Estradiol spray Lenzetto in Indian market4 Jan 2023, 9:35AM Themis Medicare informs about loss of share certificate28 Dec 2022, 3:24PM Themis Medicare informs about closure of trading window26 Dec 2022, 5:25PM Themis Medicare informs about cancellation of analyst meet 19 Dec 2022, 12:26PM Themis Medicare informs about newspaper publication 13 Dec 2022, 9:54AM Themis Medicare informs about notice of postal ballot and e-voting9 Dec 2022, 4:06PM Themis Medicare informs about transcript of conference call 21 Nov 2022, 4:58PM Themis Medicare gets nod to transfer API business to subsidiary8 Nov 2022, 10:44AM Themis Medicare - Quaterly Results7 Nov 2022, 7:37PM Themis Medicare - Quaterly Results7 Nov 2022, 7:37PM Themis Medicare informs about typographical error in board meeting intimation 31 Oct 2022, 10:58AM Themis Medicare partners with NFL Biosciences to develop NFL-1017 Oct 2022, 10:50AM Themis Medicare informs about analyst meet 22 Sep 2022, 10:54AM Themis Medicare informs about voting results of AGM21 Sep 2022, 12:20PM Themis Medicare informs about appointment of statutory auditors20 Sep 2022, 1:30PM Themis Medicare informs about analyst meet15 Sep 2022, 10:10AM Themis Medicare informs about annual report27 Aug 2022, 12:39PM

Themis Medicare Stock Price Analysis and Quick Research Report. Is Themis Medicare an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Themis Medicare and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Themis Medicare cash from the operating activity was Rs 16.0733 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Themis Medicare has a Debt to Equity ratio of 0.3264 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Themis Medicare , the EPS growth was -29.6876027524197 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Themis Medicare has OPM of 19.0397583224135 % which is a good sign for profitability.
     
  • ROE: Themis Medicare have a average ROE of 16.4929983470621 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Themis Medicare is Rs 212.85. One can use valuation calculators of ticker to know if Themis Medicare share price is undervalued or overvalued.
Last Updated on:
Brief about Themis Medicare
X